Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy that is
characterized by early metastasis, low resectability, high recurrence, and therapy resistance …

As a common gastrointestinal tumor, the incidence of pancreatic cancer has been increasing
in recent years. The disease shows multi-gene, multi-step complex evolution from …

Background Relevant preclinical models that recapitulate the key features of human
pancreatic ductal adenocarcinoma (PDAC) are needed in order to provide biologically …

Pancreatic cancer (PC) is anticipated to be second only to lung cancer as the leading cause
of cancer-related deaths in the United States by 2030. Surgery remains the only potentially …

In the last 10 years, there has been a relative explosion of new rodent systems that
recapitulate both genetic and cellular lesions that lead to the development of pancreatic …

The past several decades have seen great effort devoted to mimicking the key features of
pancreatic ductal adenocarcinoma (PDAC) in animals and have produced 2 robust models …

Pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease despite
tremendous scientific efforts. Numerous trials have failed to improve the outcome on this …

Pancreatic cancer is an inherently aggressive disease with an extremely poor prognosis and
lack of effective treatments. Over the past few decades, much has been uncovered regarding …

Unlike many other cancers, pancreatic ductal adenocarcinoma (PDAC) has seen only
incremental improvement in mortality despite significant advances in our understanding of …

Pancreatic cancer is one of the most lethal of human malignancies ranking 4th among
cancer-related death in the western world and in the United States, and potent therapeutic …